SRR29022834
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ADIPOGENESIS+0.310
- ESTROGEN_RESPONSE_EARLY+0.310
- BILE_ACID_METABOLISM+0.270
- FATTY_ACID_METABOLISM+0.250
- UV_RESPONSE_DN+0.240
- ESTROGEN_RESPONSE_LATE+0.210
- PEROXISOME+0.170
- APICAL_SURFACE+0.110
- MYOGENESIS+0.110
- P53_PATHWAY+0.110
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.660
- INTERFERON_GAMMA_RESPONSE-0.650
- ALLOGRAFT_REJECTION-0.620
- IL6_JAK_STAT3_SIGNALING-0.530
- E2F_TARGETS-0.520
- G2M_CHECKPOINT-0.520
- INFLAMMATORY_RESPONSE-0.520
- MYC_TARGETS_V2-0.480
- COMPLEMENT-0.430
- MTORC1_SIGNALING-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2278853 | — | — | 0.872 |
| 2 | TCGA-A8-A09B-01A-11R-A00Z-07 | — | B | 0.865 |
| 3 | C3N-02973 | — | cohortA1 | 0.863 |
| 4 | s0112300 | — | — | 0.861 |
| 5 | BSR_17_0022_E1_S60 | — | A | 0.861 |
| 6 | TCGA-B6-A0RQ-01A-11R-A115-07 | — | A | 0.852 |
| 7 | TCGA-AC-A2FG-01A-11R-A17B-07 | — | A | 0.842 |
| 8 | 20030017.LumA | — | B | 0.841 |
| 9 | aMVAC.P_003_TURBT_S220 | — | — | 0.837 |
| 10 | TCGA-78-7167-01A-11R-2066-07 | — | cohortA2 | 0.837 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ADIPOGENESIS | 0.310 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.310 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.270 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.250 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.240 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.210 | Idelalisib | — uncovered |
| PEROXISOME | 0.170 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.110 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.110 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.110 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.080 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.060 | Cobimetinib | — uncovered |
| HEME_METABOLISM | 0.050 | Temsirolimus | — uncovered |
| HYPOXIA | 0.030 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.030 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.020 | Remibrutinib | — uncovered |